KKR announced the acquisition of Integer Holdings for $5.7 billion, taking private a medical device contract development and manufacturing organization with exposure to cardiac rhythm management and neuromodulation. The transaction, expected to close by year-end, removes a publicly traded CDMO serving Medtronic, Abbott, and Boston Scientific at a moment when device OEMs are shedding manufacturing capacity and turning to specialized partners. Integer generated $1.56 billion in trailing revenue, putting the deal at roughly 3.7x sales—a premium to recent medtech CDMO transactions, which have settled between 2.8x and 3.2x.
Integer operates 14 manufacturing sites across five countries, with concentrations in batteries, capacitors, and enclosures for implantable devices. The company's Cardiac & Neuromodulation segment represents 68% of revenue, while the Portable Medical division—covering infusion pumps, diabetes care, and wearables—accounts for the remainder. KKR is acquiring a business with 22% operating margins and sticky customer relationships: Integer's top five clients represent 52% of revenue, and switching costs are high due to FDA design history file integrations and long qualification cycles. The deal removes Integer's public market obligations and quarterly earnings pressures, allowing KKR to pursue tuck-in acquisitions of smaller CDMOs without immediate margin scrutiny.
The transaction sits inside a broader consolidation wave in medical device outsourcing. Permira acquired Paragon Medical for $2.9 billion in 2022. Blackstone took Aesculap Implant Systems private the same year. Private equity's thesis is straightforward: device OEMs want to own IP and distribution, not factories. Integer's customer base is already outsourcing 35-40% of component production, and that figure is rising. KKR inherits multi-year supply agreements with inflation pass-throughs and capital equipment depreciation schedules that insulate margin compression. The firm also gains optionality on neuromodulation, where spinal cord stimulation and sacral nerve therapy devices are growing at 12-14% annually—faster than the broader 6-7% medtech market.
Allocators should track three follow-on events. First, whether KKR uses Integer as a platform for roll-up M&A in the $50-300 million CDMO segment, where 18-22 private companies remain fragmented. Second, any expansion into drug-device combination manufacturing, where margins run 400-600 basis points higher but require biologics facility investment. Third, the timing of any debt refinancing: Integer carries $965 million in net debt, and KKR will likely upsize that to fund bolt-ons, with syndication expected in Q1 2026 if the high-yield window cooperates. Watch for credit rating commentary from Moody's, which currently holds Integer at Ba2—one notch into junk.
The deal prices Integer at 18.2x forward EBITDA, a 22% premium to the stock's three-month average multiple, signaling KKR sees cost synergies or revenue acceleration invisible to public equity analysts. The firm is betting that device outsourcing is structural, not cyclical, and that manufacturing scale in neuromodulation is defensible enough to justify a mid-teens IRR over a seven-year hold.